Cargando…
A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial
BACKGROUND: Kawasaki disease (KD) is a systemic vasculitis complicated with coronary artery abnormalities (CAAs). Intravenous immunoglobulin reduces the occurrence of CAAs, but significant number of KD patients with CAAs still exists. Thus, new approaches to prevent and attenuate CAAs are warranted....
Autores principales: | Murata, Yo, Isayama, Reina, Imai, Shoko, Shoji, Kensuke, Youndzi, Mizuho, Okada, Mami, Mikami, Masashi, Kobayashi, Shinobu, Urayama, Kevin Y., Kobayashi, Tohru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844785/ https://www.ncbi.nlm.nih.gov/pubmed/35198792 http://dx.doi.org/10.1016/j.conctc.2022.100892 |
Ejemplares similares
-
Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023) -
RNA Sequencing Reveals Beneficial Effects of Atorvastatin on Endothelial Cells in Acute Kawasaki Disease
por: Shimizu, Chisato, et al.
Publicado: (2022) -
Exposures associated with the onset of Kawasaki disease in infancy from the Japan Environment and Children’s Study
por: Fukuda, Sayaka, et al.
Publicado: (2021) -
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)
por: Livingstone, Shona J., et al.
Publicado: (2015) -
Safety of atorvastatin in Asian patients within clinical trials
por: Chan, Juliana C. N., et al.
Publicado: (2016)